Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | NCF1 | P14598 | 11/20 | 0.47 |
| ▸ | CYBB | P04839 | 3/20 | 0.46 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23412198 | 0.85 | NCF1 (0.66) | NCF1CYBBNOX5 | |
| SCHEMBL13040594 | 0.80 | NCF1 (0.50) | CYP2A6NCF1CYBBNOX5 | |
| SCHEMBL2905129 | 0.77 | DCPS (0.50) | NCF1CYBBNOX5MAPT | |
| SCHEMBL19690941 | 0.76 | CYP3A4 (0.47) | CYP3A4CYP2A6MAOBMAPT | |
| SCHEMBL19690948 | 0.76 | SETDB1 (0.60) | CYP3A4CYP2A6NCF1CYBBNOX5 | |
| SCHEMBL2242312 | 0.76 | NCF1 (0.56) | NCF1CYBBNOX5 | |
| SCHEMBL19690936 | 0.75 | SETDB1 (0.66) | CYP3A4CYP2A6NCF1CYBBNOX5 | |
| SCHEMBL19038909 | 0.74 | CYP3A4 (0.57) | CYP3A4CYP2A6MAOBMAPT | |
| SCHEMBL2242668 | 0.74 | GRM5 (0.54) | NCF1CYBBNOX5MAPT | |
| SCHEMBL12353493 | 0.74 | NCF1 (0.42) | NCF1CYBBNOX5MAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9980954-B2 | Quinoline derivatives for inhibiting histone methyltransferases and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-05-29 | — | — | US | disclosed |
| US-20170354650-A1 | QUINOLINE DERIVATIVES FOR INHIBITING HISTONE METHYLTRANSFERASES AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170354650-A1 | QUINOLINE DERIVATIVES FOR INHIBITING HISTONE METHYLTRANSFERASES AND USE THEREOF | NSD1, EHMT1, SETDB1 | CYP3A4 3799/4885CYP2A6 4751/4885NCF1 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.